Nautilus Biotechnology Inc (NAUT) — Titan Protect Analysis

NAUT

Nautilus Biotechnology Inc

Healthcare · ·

$2.39

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$335M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-3.57

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-33.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$4.00

+67% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 1 analysts covering this stock

About Nautilus Biotechnology Inc

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to

https://www.nautilus.bio

Country: United States Employees: 127 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.466

Positive but modest risk-adjusted returns

Kelly Fraction

0.0037

Marginal edge — very small allocation suggested

Calmar Ratio

0.024

Drawdown risk outweighs the returns — higher risk profile

Annual Return

1.9%

Historical annualised return based on price data

Max Drawdown

-79.3%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.75

Less volatile than the market — more defensive

52W High

$4.31

45% below the year high

52W Low

$0.62

285% above the year low

Avg Volume

369,617

Average daily shares traded — higher means easier to buy and sell

Short Ratio

2.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.46

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

19.99

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-28,882,124

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-57,085,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$4.00

Target Median

$4.00

Target Low

$4.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go